ibogaine in the treatment of chronic hepatitis c
Skip this Video
Download Presentation
Ibogaine in the treatment of chronic hepatitis C

Loading in 2 Seconds...

play fullscreen
1 / 22

Ibogaine in the treatment of - PowerPoint PPT Presentation

  • Uploaded on

Ibogaine in the treatment of chronic hepatitis C. Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NY http://www.doraweiner.org. Invitational Ibogaine forum Warsaw 2007 Wednesday 16 May Hotel Sofitel Victoria. Tabernanthe iboga source of ibogaine.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Ibogaine in the treatment of' - medwin

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
ibogaine in the treatment of chronic hepatitis c

Ibogaine in the treatment ofchronic hepatitis C

Howard S. Lotsof.


Dora Weiner Foundation

Staten Island, NY


Invitational Ibogaine forum

Warsaw 2007

Wednesday 16 May

Hotel Sofitel Victoria

tabernanthe iboga source of ibogaine
Tabernanthe ibogasource of ibogaine

Found in West African rain forests

purified ibogaine hcl
Purified Ibogaine HCl

Courtesy Jason Callan

President and Founder

Ethnogarden Botanical


hepatitis c hcv timeline
Hepatitis C (HCV)timeline

1973: Non A, Non B hepatitis is described

1989: HCV RNA virus identified

1990: Anti HCV effects of ibogaine reported

2005: Patent application for ibogaine to treat chronic HCV filed

hcv infection
HCV infection

Most common viral infection in the

United States

New infections per year 1990 - 242,000

New infections per year 2001 - 25,000

New infections per year 2004 - 25,000

Greater than 75% of IVDUs test positive

science follows patent development
Science follows patent development

The discovery of ibogaine’s use in treating both chemical dependence and HCV was by ibogaine activist advocates who were themselves treated or self-treated with ibogaine.

Scientific research followed patent development in the treatment of chemical dependence and it is hoped the same will be true for ibogaine related HCV research.

ibogaine patents
Ibogaine Patents

Rapid method for interrupting the narcotic addiction syndrome, US 4,499,096 (1985)

Rapid method for interrupting the cocaine and amphetamine abuse syndrome US 4,587,243 (1986)

Rapid method for attenuating the alcohol dependency syndrome, US 4,957,523 (1989)

Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US 5,026,697 (1991)

Rapid method for interrupting or attenuating poly-drug dependency syndromes, US 5, 124,994 (1992)

research follows skepticism
Research follows skepticism
  • Broad ranging claims of ibogaine to treat multiple forms of chemical doubted
  • Over time, all claims for chemical dependence have been confirmed by research
      • Opioids,
      • stimulants,
      • Alcohol
      • nicotine
ibogaine activist organizations play role in ibogaine hcv research
Ibogaine activist organizations playrole in ibogaine HCV research
  • International Coalition for Addict Self-Help (ICASH) 1989
  • Dutch Addict Self-Help (DASH) 1990
  • Ibogaine Underground 2004
example 1 report
Example 1 Report

A thirty-three year old male diagnosed with HCV and using 1/4 gram of heroin a day was administered 25 mg/kg ibogaine HCl. Following administration of ibogaine heroin use ceased along with swelling of the liver and pain in the area of the liver.

example 3
Example 3

A sixty year old male testing positive for HCV RNA genotype I, administered the following dose regimens of ibogaine HCl. Subject weighed 79 kg. Doses administered were as total doses and not mg/kg. Day 1: 10 mg, Day 2: 20 mg, Day 3: 20 mg, Day 4: 30 mg, Day 5: 50 mg, Day 6: 75 mg, Day 8: 100 mg.Day 10: 150 mg, Day 14: 300 mg. HCV RNA UL/ml was reduced from 780,000 to 644,000, Pretreatment Alkaline Phosphatase was 99, AST was 103 and ALT 195. Post treatment Alkaline Phosphatase was 88, AST 89 and ALT 127. An additional 250 mg ibogaine HCl reduced HCV RNA UL/ml to 154,000. Further testing showed continued reduction to HCV RNA UL/ml 78,200

example 4
Example. 4

A forty-two year old female testing positive for HCV RNA type 3. RNA IU/ml was 12,600,000. Subject was administered a total of 27 mg/kg ibogaine HCl in the following regimen:

6 x 2 mg/kg

1 x 12 mg/kg

1 x 3 mg/kg

HCV RNA IU/ml was reduced to 50,100. Prior to ibogaine treatment patient’s urine was dark and stool light. Post treatment color of urine and stool returned to normal.

encouraging results
Encouraging results

Repetitive low dosing with ibogaine provided continuous depression of viral load.

Genotype 3 appears highly responsive in keeping with results of interferon riboviron therapy.

Continued reduction in viral load after stopping of ibogaine therapy observed.

Less toxic than current HCV therapies.

future development
Future development

Interest of pharmaceutical companies with experience in development of HCV drugs.

Preclinical confirmation of efficacy if possible.

Phase I/II clinical studies to confirm findings and establish preferred dose regimen.